Contact
searchSearch
HMP Global
Login

HRR

Videos

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
Selecting PARP Inhibitors for Patients With ER-Positive Early Breast Cancer
12/12/2023
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of...
12/12/2023
Oncology
Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre
Videos
Prevalence of DNA Repair Defects Among Patients With Metastatic Prostate Cancer
11/02/2023
Shahneen Sandhu, MBBS
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational...
11/02/2023
Oncology
Elena Castro, MD, PhD Hospital Universitario 12 de Octubre
Videos
Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations
11/01/2023
Elena Castro, MD, PhD
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final...
11/01/2023
Oncology
Eleni Efstathiou, MD, Houston Methodist Cancer Center
Videos
Niraparib Plus Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer and HRR Alterations
02/27/2023
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary...
02/27/2023
Oncology
Erika Hamilton, MD
Videos
Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Claire Harrison, MD
Videos
Selinexor Plus Ruxolitinib as a Frontline Combination in Patients With Myelofibrosis
06/26/2026
Claire Harrison, MD
Claire Harrison, MD, discusses results from the phase 3 SENTRY trial showing that selinexor plus ruxolitinib significantly improved spleen responses and overall survival while demonstrating evidence of disease modification in patients with...
Claire Harrison, MD, discusses results from the phase 3 SENTRY trial showing that selinexor plus ruxolitinib significantly improved spleen responses and overall survival while demonstrating evidence of disease modification in patients with...
Claire Harrison, MD, discusses...
06/26/2026
Oncology
Claire Harrison, MD
Videos
First-in-Class Mutant CALR Antibody Demonstrates Durable Clinical Activity in Myelofibrosis
06/26/2026
Claire Harrison, MD
Claire Harrison, MD, discusses updated phase 1 data showing that the mutant CALR-targeted monoclonal antibody INCA033989 produced meaningful clinical and molecular responses with a favorable safety profile in patients with CALR-mutant...
Claire Harrison, MD, discusses updated phase 1 data showing that the mutant CALR-targeted monoclonal antibody INCA033989 produced meaningful clinical and molecular responses with a favorable safety profile in patients with CALR-mutant...
Claire Harrison, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
Concurrent Thoracic Radiotherapy, Platinum/Etoposide Chemotherapy, and Durvalumab Immunotherapy Does Not Improve Outcomes in Extensive-Stage Small Cell Lung Cancer
06/26/2026
Bjørn Henning Grønberg, MD, PhD, professor and consultant in oncology at the Norwegian University of Science and Technology and St. Olavs Hospital in Trondheim, Norway, discusses results from a phase 3 randomized trial evaluating the addition...
Bjørn Henning Grønberg, MD, PhD, professor and consultant in oncology at the Norwegian University of Science and Technology and St. Olavs Hospital in Trondheim, Norway, discusses results from a phase 3 randomized trial evaluating the addition...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
Health-Related Quality of Life Preserved with Neoadjuvant and Adjuvant Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
06/26/2026
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
Pralsetinib Shows Improved Response in RET Fusion–Positive Advanced or Metastatic Non–Small Cell Lung Cancer
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
Vorasidenib Maintains Durable Clinical Benefit With Consistent Safety in IDH-Mutated Glioma
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology
Kevin Kalinsky, MD
Videos
Frontline Sacituzumab Govitecan Continues to Show Benefit in PD-L1–Positive Triple-Negative Breast Cancer
06/24/2026
Kevin Kalinsky, MD, MS
Kevin Kalinsky, MD, discusses updated results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab continued to provide durable clinical benefit beyond initial progression, supporting its use as a frontline treatment...
Kevin Kalinsky, MD, discusses updated results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab continued to provide durable clinical benefit beyond initial progression, supporting its use as a frontline treatment...
Kevin Kalinsky, MD, discusses...
06/24/2026
Oncology

News

Conference Coverage
Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations
01/25/2024
Allison Casey
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial,...
01/25/2024
Oncology
News
Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer
10/16/2023
Allison Casey
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed...
10/16/2023
Oncology
News
PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer
09/26/2023
Allison Casey
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and...
09/26/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer
09/14/2023
Allison Casey
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis...
09/14/2023
Oncology
News
Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer
07/26/2023
Stephanie Holland
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the...
07/26/2023
Oncology
News
Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
06/21/2023
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA...
06/21/2023
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

Quizzes

Quiz
Progression-Free Survival Outcomes With Pegylated Liposomal Doxorubicin in Patients With Desmoid Tumors
06/19/2026
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated...
06/19/2026
Oncology
Quiz
Tiragolumab Plus Atezolizumab and Chemotherapy in ES-SCLC
06/19/2026
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory...
06/19/2026
Oncology
Quiz
Safety and Preliminary Activity of Eganelisib in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/19/2026
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a...
06/19/2026
Oncology
Quiz
Polycythemia Vera Management Pre-Survey
06/17/2026
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in...
06/17/2026
Oncology
Quiz
Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasms
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology
Quiz
Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer
06/08/2026
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase...
06/08/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 4
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 3
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 2
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 1
05/21/2026
Lucia Masarova, MD
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the...
05/21/2026
Oncology
OLN

HRR

ALIASES

Human recombination repair

References

Homologous recombination repair (HHR) is a DNA repair mechanism that removes damaged DNA by acting on double-strand breaks, interstrand crosslinks, and other kinds of DNA damage.1 DNA damage is repaired with high fidelity by correcting damage with information copied from a homologous undamaged molecule.2 Defects in HRR are present in some cancers.3

Recent News

Conference Coverage
Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations
01/25/2024
Allison Casey
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial,...
01/25/2024
Oncology
News
Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer
10/16/2023
Allison Casey
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed...
10/16/2023
Oncology
News
PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer
09/26/2023
Allison Casey
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and...
09/26/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer
09/14/2023
Allison Casey
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis...
09/14/2023
Oncology
News
Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer
07/26/2023
Stephanie Holland
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the...
07/26/2023
Oncology
News
Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
06/21/2023
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA...
06/21/2023
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use